MedTrace Logo

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

NCT06574620 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-01-16

No results posted yet for this study

Summary

The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are:

* Is it feasible to obtain genetic test results within a timeframe that can help inform treatment decisions for individuals with PDAC?
* Can the genetic test results provide information about how a tumour will respond to or resist treatment?

Participants will:

* Receive standard chemotherapy to treat their cancer.
* Provide samples of their blood, tissue, and fluid for genetic testing.
* Visit the clinic every 4 weeks for check-ups and tests.
* Complete questionnaires every 12 weeks.

Conditions

  • Pancreatic Ductal Adenocarcinoma
  • Resectable Pancreatic Ductal Adenocarcinoma
  • Borderline Resectable Pancreatic Ductal Adenocarcinoma
  • Locally Advanced Pancreatic Ductal Adenocarcinoma

Interventions

GENETIC

Genetic testing

Analyses of the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, and other molecules in the sample.

PROCEDURE

Optional biopsy

Optional collection of tumour tissue and normal tissue after the last dose of treatment.

PROCEDURE

Tissue collection

Collection of tumour tissue and normal tissue from biopsy or standard resection surgery prior to the first dose of treatment.

Sponsors & Collaborators

  • Terry Fox Research Institute

    collaborator OTHER

  • BC Cancer Foundation

    collaborator OTHER

  • British Columbia Cancer Agency

    lead OTHER

Principal Investigators

  • Daniel J Renouf, MD · BC Cancer

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-28
Primary Completion
2028-12-31
Completion
2031-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06574620 on ClinicalTrials.gov